<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01348724</url>
  </required_header>
  <id_info>
    <org_study_id>D3820C00001</org_study_id>
    <nct_id>NCT01348724</nct_id>
  </id_info>
  <brief_title>Absorption, Distribution, Metabolism and Excretion (ADME) Study With Single Oral Administration of [14C] NKTR-118</brief_title>
  <official_title>A Phase I, Open-Label, Single-Centre Study to Assess Absorption, Distribution, Metabolism and Excretion (ADME) After [14C]-Labelled Oral Administration of NKTR-118 to Healthy Male Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <brief_summary>
    <textblock>
      Study to Assess the Absorption, Metabolism and Excretion of [14C] NKTR-118 after a
      Single-Dose Oral Administration.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2011</start_date>
  <completion_date type="Actual">September 2011</completion_date>
  <primary_completion_date type="Actual">September 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of radioactive dose recovered in urine and feces samples and the total percentage of radioactive dose recovered in both urine and feces</measure>
    <time_frame>Range of Day 1 until day 10</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Concentration of total radioactivity in blood and plasma samples</measure>
    <time_frame>Range of Day 1 until day 10</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Concentration of NKTR-118 in blood and plasma sample</measure>
    <time_frame>Range of Day 1 until day 10</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability of NKTR-118 following administration of a single oral dose of [14] NKTR-118 solution by assessing adverse event</measure>
    <time_frame>Range of Day -1 until follow up visit (Visit 3)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability of NKTR-118 following administration of a single oral dose of [14] NKTR-118 solution by assessing vital signs</measure>
    <time_frame>Range of Day -1 until follow up visit (Visit 3)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability of NKTR-118 following administration of a single oral dose of [14] NKTR-118 solution by assessing safety blood samples</measure>
    <time_frame>Range of Day -1 until follow up visit (Visit 3)</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>[14C] NKTR-118</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>[14C] NKTR-118</intervention_name>
    <description>Single 25 mg oral dose administered on Day 1</description>
    <arm_group_label>[14C] NKTR-118</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Have a body mass index (BMI) of ≥18 and ≤30 kg/m2 and a minimum weight of 50 kg

          -  Regular daily bowel movements (ie, production of at least 1 stool per day).

          -  Non-smoker or ex-smoker who has not used tobacco or nicotine products for ≥3 months
             prior to Visit 1

        Exclusion Criteria:

          -  Healthy volunteers who have been exposed to radiation levels above background (eg,
             through X-ray examination) of &gt;5 mSv in the last year, &gt;10 mSv in the last 5 years, or
             a cumulative total of &gt;1 mSv per year of life

          -  Participation in any prior radiolabelled study within 12 months of screening visit 1

          -  Excessive intake of caffeine containing drinks e.g., coffee, tea, caffeine containing
             energy drinks and cola (more than 5 cups of coffee or equivalent per day
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marianne Kasti, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Quintiles, Inc.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mark Sostek, PhD</last_name>
    <role>Study Director</role>
    <affiliation>AstraZeneca</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Emeline Ramos</last_name>
    <role>Study Chair</role>
    <affiliation>AstraZeneca</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&amp;studyid=1385&amp;filename=D3820C00001_Clinical_Study_Report_Synopsis.pdf</url>
    <description>Clinical Study Report Synopsis</description>
  </link>
  <verification_date>October 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 21, 2011</study_first_submitted>
  <study_first_submitted_qc>May 4, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 5, 2011</study_first_posted>
  <last_update_submitted>October 13, 2014</last_update_submitted>
  <last_update_submitted_qc>October 13, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 15, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Radioactive carbon</keyword>
  <keyword>Absorption</keyword>
  <keyword>Distribution</keyword>
  <keyword>Metabolism</keyword>
  <keyword>Excretion</keyword>
  <keyword>Healthy Volunteers</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Naloxegol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

